Features
-
Animal-derived component-free
-
Protein-free/Peptide ingredients-free
-
Chemically Defined
-
DMF Filing in Progress
-
Universality: Support the culture of various CHO cell lines (CHO-K1, CHO_ZN, Horizon, CHO-S, CHO DG44, etc.) in fed-batch, intensified fed-batch and perfusion modes
Advantages
Equivalent or superior performance to global brand products with better price and lead time
4 advanced CMPM (Cone Mixing Pin Milling) powder media production lines to meet different customer demand with high inter-batch consistency (CPK*>1.33)
Safe and compliant: chemically defined formulation minimizes the potential of contamination from animal-derived components and meets relevant compliance and regulatory requirements
EU certified ISO13485:2016 QMS and MDSAP (FDA), all data are traceable
Full documentation support available for IND application
Strictly selected the "2 domestic+1 imported" raw material supplier model to to ensure a stable and reliable supply chain
*CPK is a standard index to state the capability of one process. CPK=1.33: the process is capable and meets specification limits. The higher the CPK,the better.
Order Information
Basal Medium
Fed-Batch Cultures
Application |
Product Name |
Cat. No. |
Size |
Form |
Instructions (PDF) |
Inquiries /Sample Applications |
CHO-K1, CHO-ZN, HORIZON, CHO-S, and CHO DG44, etc. |
Eden B600S Basal Medium |
EXP0109901 |
10 L |
Powder |
Download |
|
EXP0109902 |
200 L |
Powder |
||||
Eden B501S Basal Medium |
EXP0106001 |
10 L |
Powder |
Download |
||
EXP0106002 |
200 L |
Powder |
||||
Eden B401S Basal Medium |
EXP0105901 |
10 L |
Powder |
Download |
||
EXP0105902 |
100 L |
Powder |
||||
EXP0105903 |
200 L |
Powder |
||||
Eden B300S Basal Medium |
EXP0107901 |
100 L |
Powder |
Download |
||
EXP0107902 |
200 L |
Powder |
||||
EXP0107903 |
10 L |
Powder |
Application |
Product Name |
Cat. No. |
Size |
Form |
Product Instruction (pdf) |
Inquiries /Sample application |
CHO-K1, CHO-ZN, HORIZON, CHO-S, and CHO DG44, etc. |
Eden F601aS Feed Medium |
EXP0112101 |
20 L |
Powder |
Download |
|
EXP0112102 |
10 L |
Powder |
||||
EXP0112103 |
1 L |
Powder |
||||
Eden F600aS Feed Medium |
EXP0108901 |
20 L |
Powder |
Download |
||
EXP0108902 |
10 L |
Powder |
||||
EXP0108903 |
1 L |
Powder |
||||
Eden F500aS Feed Medium |
EXP0105001 |
1 L |
Powder |
Download |
||
EXP0105002 |
20 L |
Powder |
||||
Eden F400aS Feed Medium |
EXP0104801 |
1 L |
Powder |
Download |
||
EXP0104802 |
20 L |
Powder |
||||
Eden F600bS Feed Medium |
EXP0108801 |
10 L |
Powder |
Download |
||
EXP0108802 |
1 L |
Powder |
||||
Eden F200bS Feed Medium |
EXP0104601 |
1 L |
Powder |
Download |
||
EXP0104602 |
10 L |
Powder |
||||
EXP0104603 |
20 L |
Powder |
||||
EXP0104604 |
50 L |
Powder |
Performance
Antibodies
In fed-batch process, CHO cells cultured in Eden CD CHO media demonstrate higher viable cell density (VCD) and protein production than competitors. On average, the antibody titers of various CHO cell lines cultured in Eden CD CHO media ranged from 2 to 11 g/L.
In the pulse perfusion process, CHO cells cultured in Eden CD CHO media demonstrated superior performance than competitive global brands. When VVD=1.0, volumetric productivity (Vp) can reach up to 2.2 g/L/day, and the cumulative product expression in 14 days can reach 19 g/L, 55% higher than global brand B. When VVD=2.0, Vp can reach up to 3.3g/L/day, and the cumulative product expression in 14 days can reach 25 g/L.
Documents
CHO Cell Medium
FAQ
Q1: Why does BioEngine's provided solution not involve cooling, which is commonly practiced in cultivation processes?
Q2: How do you perform media exchange during perfusion cell culture?
Q3: In a 500L reactor, if the pH keeps decreasing over time, what could be the reason?
Q4: What is in DMEM media?
Q5: What is CAR-T therapy?
CAR-T therapy has been approved by the FDA for certain types of B cell leukemia and lymphoma, such as acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, and multiple myeloma. However, CAR-T therapy also has some limitations and challenges, such as severe side effects, antigen escape, poor trafficking and tumor infiltration, and immunosuppressive microenvironment. Researchers are working on improving CAR-T therapy by developing new strategies and approaches to overcome these barriers.
BioEngine’s HIPP T009 medium can support rapid expansion of CAR-T cells which could reduce the waiting period for patients, and ensure CAR positivity rate to guarantee product efficacy and quality.
Q6: Are there any recommendations for preventing or dispersing cell clumps in a suspension culture?
1. Use fresh media: Old media can contain debris or dead cells that may promote clumping. Therefore, it is important to use fresh media to ensure the best conditions for cell growth.
2. Gentle pipetting: Avoid harsh pipetting which may lead to the formation of cell clumps. Instead, use a gentle pipetting technique that helps disperse the cells.
3. Use anti-clumping agents: Anti-clumping agents such as Pluronic F-68, HEPES, or EDTA can be added to the media to help prevent cell clumping. These agents work by reducing the surface tension between the cells, making them less likely to stick together.
4. Use agitation: Agitation can be used to promote the dispersal of cell clumps. Methods such as shaking, stirring, or spinning the culture can help break up the clumps.
5. Use enzymatic treatments: Enzymes such as trypsin, collagenase, or DNase can be added to the culture to help disperse cell clumps. These enzymes work by breaking down the components that promote cell clumping.
Overall, the key to preventing or dispersing cell clumps is to maintain the culture in the best conditions possible, with a focus on gentle handling and the use of appropriate agents or treatments as needed. For any inquiries regarding cell culture, please reach out to us and our technical support team will provide you with optimal solutions.
Q7:Why do we use insect cells for protein expression?
Q8: What are the differences between CAR-T and uCAR-T?
The main difference between CAR-T and UCAR-T is that CAR-T cells are autologous, meaning they are made from the patient’s own T cells, while UCAR-T cells are allogeneic, meaning they are made from healthy donors’ T cells.
The advantage of UCAR-T cells is that they can be produced in advance and used for multiple patients, which may reduce the cost, time and variability of CAR-T cell therapy. However, UCAR-T cells also face the challenge of avoiding immune rejection and graft-versus-host disease (GVHD), which may require gene editing techniques to remove or modify certain antigens on the donor T cells."
Q9: Why are Vero cells used for vaccines?
Q10: What are T cells?
T cells have a special molecule called a T cell receptor (TCR) on their surface, which can bind to antigens presented by other cells. T cells develop in the bone marrow and mature in the thymus, which is why they are also called T lymphocytes.
There are two main types of T cells: cytotoxic T cells and helper T cells. Cytotoxic T cells (also called CD8+ T cells) can directly kill infected or cancerous cells by releasing toxic substances. Helper T cells (also called CD4+ T cells) can secrete cytokines that stimulate other immune cells, such as B cells and macrophages, to produce antibodies and destroy pathogens.
There are also other subtypes of T cells, such as regulatory T cells, which can suppress excessive or harmful immune responses and prevent autoimmune diseases, and memory T cells, which can provide long-lasting immunity against previously encountered antigens."
Q11: What is the best medium for T cells?
Q12: Can BioEngine provide culture medium development services?
Previous
No InformationNext
No Informationhttp://www.bioengine-global.com/